You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天宇股份(300702.SZ):子公司維格列汀片獲批上市
格隆匯 06-27 17:21

格隆匯6月27日丨天宇股份(300702.SZ)公佈,公司全資子公司浙江諾得藥業有限公司(簡稱“諾得藥業”)於近日收到國家藥監局核准簽發的關於維格列汀片的《藥品註冊證書》。

維格列汀片屬於胰島素增敏劑類,該藥物是一種高效的選擇性二肽-肽酶-4(DPP-4)抑制劑,由諾華(Novartis)研發並於2007年獲准在歐盟上市,用於治療2-型糖尿病。

根據國家藥監局網站數據查詢,截至公吿日,該規格製劑除諾得藥業外,國內生產商另有江蘇豪森藥業集團有限公司、海南通用三洋藥業有限公司等15家企業。

據統計,2021年維格列汀片在國內樣本醫院(包括城市公立醫院,城市社區醫院,縣級公立醫院,鄉鎮衞生院)和城市實體藥店的銷售額約人民幣1.5億元(數據來源於米內網)。

諾得藥業維格列汀片50mg規格於2020年12月獲得國家藥監局受理,目前公司及子公司累計投入費用約709萬元。

公司表示,其產品維格列汀片獲得國家藥監局批件後即可在境內生產、銷售,進一步豐富了公司的製劑品種,有望增加公司製劑業務收入,有助於提升公司產品的市場競爭力,對公司的經營業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account